Advertisement

Pharmaceutical Research

, Volume 22, Issue 7, pp 1069–1078 | Cite as

Nontoxic Suramin Treatments Enhance Docetaxel Activity in Chemotherapy-Pretreated Non-Small Cell Lung Xenograft Tumors

  • Ze Lu
  • Trini S.-S. Wientjes
  • Jessie L.-S. Au
Research Paper

Purpose

We reported that nontoxic suramin treatments enhance the activity of chemotherapy in preclinical models, a finding supported by the results of subsequent phase I/II trials in chemotherapy-naive non-small cell lung cancer (NSCLC) patients who received/carboplatin (P/C) combination therapy. The present study evaluated whether suramin enhances the activity of docetaxel in human NSCLC xenografts.

Methods

The in vitro effect of suramin on docetaxel activity was evaluated using 3-D histocultures of chemotherapy-naive A549 tumors. For in vivo activity evaluation, we first established the P/C pretreatment schedule that produced tumor growth inhibition, but not tumor eradication, and established the maximally tolerated docetaxel/suramin regimens. In the second study, P/C-treated animals received physiological saline, single-agent suramin (10 mg/kg), docetaxel (10 mg/kg), or the combination twice weekly for 3 weeks.

Results

The in vitro results showed that 20 μM suramin, which had no activity as single agent, enhanced the docetaxel activity (measured as 50% inhibition of DNA synthesis) by more than 10-fold. The in vivo studies showed reduced tumor growth by P/C (30% growth in 14 days vs. 75% in control). In contrast, docetaxel produced tumor regression (15% reduction) in P/C-treated animals, significantly reduced, on a cellular level, the viable cell density and the proliferating fraction (40% reduction for both measurements), and enhanced the apoptotic fraction 4-fold (p < 0.05 for all effects). Suramin had no activity or toxicity (measured as body weight loss) but significantly enhanced the docetaxel activity. Compared to docetaxel alone, the combination showed earlier onset of tumor size reduction, greater extent of tumor regression (31 vs. 15%), greater reduction of viable cell density and proliferating fraction (additional 15–25% reduction), and greater apoptotic fraction (additional 2.5-fold increase) (p < 0.05 for all parameters).

Conclusions

Results of the present study indicate that nontoxic suramin treatments enhanced the activity of docetaxel in P/C-pretreated A549 xenograft tumors in mice without enhancing host toxicity. These encouraging results provided the basis for phase I/II trials of docetaxel plus low-dose suramin in patients with NSCLC in second-/third-line settings.

Key Words

chemosensitization docetaxel in vivo chemoresistance model low-dose suramin lung cancer 

Abbreviations

aFGF

acidic fibroblast growth factor

bFGF

basic fibroblast growth factor

BrdU

bromodeoxyuridine

IC50

concentration producing 50% inhibition of DNA precursor

NSCLC

non-small cell lung cancer

P/C

paclitaxel/carboplatin

Notes

Acknowledgments

This work was supported in part by research grant R01CA97067 from the National Cancer Institute, DHHS, and by a grant from Aventis Inc.

References

  1. 1.
    Song, S., Wientjes, M. G., Gan, Y., Au, J. L. 2000Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance toanticancer drugsProc. Natl. Acad. Sci. USA9786588663Google Scholar
  2. 2.
    Betscholtz, C., Johnsson, A., Heldin, C.-H., Westermark, B. 1986Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suraminProc. Natl. Acad. Sci. USA8364406444Google Scholar
  3. 3.
    Coffey, R. J., Goustin, A. S., Soderquist, A. M., Shipley, G. D., Wolfshohl, J., Carpenter, G., Moses, H. L. 1987Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine modelCancer Res.4745904594Google Scholar
  4. 4.
    Garrett, J. S., Coughlin, S. R., Niman, H. L., Tremble, P. M., Giels, G. M., Williams, L. T. 1984Blockade of autocrine stimulation in simian sarcoma virus transformed cells reverses down-regulation of platelet-derived growth factor receptorsProc. Natl. Acad. Sci. USA8174667470Google Scholar
  5. 5.
    Hosang, M. 1985Suramin binds to platelet-derived growth factor and inhibits its biological activityJ. Cell. Biochem.29265273Google Scholar
  6. 6.
    Myers, C. E., LaRocca, R., Stein, C., Cooper, M., Dawson, N., Choyke, P., Linehan, M., Urich, M. 1990Treatment of hormonally refractory prostate cancer with suraminProc. Am. Soc. Clin. Oncol.9113Google Scholar
  7. 7.
    Pollak, M., Richard, M. 1990Suramin blockade of insulinlike growth factor I-Stimulated proliferation of human osteosarcoma cellsJ. Natl. Cancer Inst.8213491352Google Scholar
  8. 8.
    Williams, L. T., Tremble, P. M., Lavin, M. F., Sunday, M. E. 1984Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studiesJ. Biol. Chem.25952875294Google Scholar
  9. 9.
    A. Ogden, S.-H. Song, M. G. Wientjes, and J. L. S. Au. Nontoxic doses of suramin enhance the activity of gemcitabine and paclitaxel in human pancreatic tumors. Proc. Am. Assoc. Cancer Res. 45 [Abstract #2148] (2003).Google Scholar
  10. 10.
    Song, S., Wientjes, M. G., Walsh, C., Au, J. L. 2001Nontoxic doses of suramin enhance activity of paclitaxel against lung metastasesCancer Res.6161456150Google Scholar
  11. 11.
    Y. Xin, D. Chen, S. Song, G. Lyness, M. G. Wientjes, and J. L. S. Au. Low-dose suramin enhances antitumor activity of mitomycin C in bladder tumors. Proc. Am. Assoc. Cancer Res. 45: (2003).Google Scholar
  12. 12.
    B. Yu, S.-H. Song, M. G. Wientjes, and J. L. S. Au. Suramin enhances activity of CPT-11 in human colorectal xenograft tumors. Proc. Am. Assoc. Cancer Res. 44:174 (2003).Google Scholar
  13. 13.
    Zhang, Y., Song, S.-H., Au, J. L. S., Wientjes, M. G. 2001Nontoxic doses of suramin enhances activity of doxorubicin in prostate tumorsJ. Pharmacol. Exp. Ther.299426433Google Scholar
  14. 14.
    G. Lyness, S. Jang, Y. Gan, Y. Zhang, M. G. Wientjes, J. L. S. Au. Fibroblast growth factors and chemoresistance in renal cell carcinomas. Proc. Am. Assoc. Cancer Res. 43:953 (2002).Google Scholar
  15. 15.
    Villalona-Calero, M. A., Otterson, G. A., Wientjes, M. G., Murgo, A., Jensen, R., Yeh, T.-K., Chen, D., Song, S., Grever, M., Au, J. L. S. 2003Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patientsLung Cancer41149Google Scholar
  16. 16.
    Villalona-Calero, M. A., Wientjes, M. G., Otterson, G. A., Kanter, S., Young, D., Murgo, A., Fischer, B., DeHoff, C., Chen, D., Song, S.-H., Au, J. L. S. 2003Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small lung cancerClin. Cancer Res.933033311Google Scholar
  17. 17.
    Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J.J., Jablons, D. M., Langer, C. J., DeVore, R. F.,III, Gaudreault, J., Damico, L. A., Holmgren, E., Kabbinavar, F. 2004Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJ. Clin. Oncol.2221842191Google Scholar
  18. 18.
    Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., Johnson, D. H. 2002Comparison of four chemotherapy regimens for advanced non-small-cell lung cancerN. Engl. J. Med.3469298Google Scholar
  19. 19.
    Fossella, F. V., Lee, J. S., Hong, W. K. 1997Management strategies for recurrent non-small cell lung cancerSemin. Oncol.24455462Google Scholar
  20. 20.
    Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., Gandara, D., Karp, D., Vokes, E., Kris, M., Kim, Y., Gamza, F., Hammershaimb, L. 2000Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study GroupJ. Clin. Oncol.1823542362Google Scholar
  21. 21.
    Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D.,Jr., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., Baird, A., Pazdur, R. 2004United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tabletsClin. Cancer Res.1012121218Google Scholar
  22. 22.
    Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., Meyerson, M. 2004EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience30414971500Google Scholar
  23. 23.
    Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., Marinis, F., Pawel, J., Gatzemeier, U., Tsao, T. C., Pless, M., Muller, T., Lim, H. L., Desch, C., Szondy, K., Gervais, R., Shaharyar, , Manegold, C., Paul, S., Paoletti, P., Einhorn, L., Jr., P. A.,Jr. 2004Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ. Clin. Oncol.2215891597Google Scholar
  24. 24.
    Gan, Y., Wientjes, M. G., Badalament, R. A., Au, J. L. S. 1996Pharmacodynamics of doxorubicin in human bladder tumorsClin. Cancer Res.212751283Google Scholar
  25. 25.
    Gan, Y., Wientjes, M. G., Schuller, D. E., Au, J. L. S. 1996Pharmacodynamics of taxol in human head and neck tumorsCancer Res.5620862093Google Scholar
  26. 26.
    Elferink, F., Vijgh, W. J., Klein, I., Bokkel Huinink, W. W., Dubbelman, R., McVie, J. G. 1988Pharmacokinetics of carboplatin after intraperitoneal administrationCancer Chemother. Pharmacol.215760Google Scholar
  27. 27.
    Tinker, N., Spiegeleer, B., Sharma, H., Jackson, H., McAuliffe, C., Reman, J. P. 1990The tissue distribution in rats of [195mPt]carboplatin following intravenous, intraperitoneal and oral administrationInt. J. Radiat. Appl. Instrum., B17427436Google Scholar
  28. 28.
    Gold, R., Schmied, M., Giegerich, G., Breitschopf, H., Hartung, H. P., Toyka, K. V., Lassmann, H. 1994Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniquesLab. Invest.71219225Google Scholar
  29. 29.
    Gu, B., Wu, D., Lu, H., Li, M., Gao, H., Wan, Y. 2001Potentiation of docetaxel antitumor activity by batimastat against mouse forestomach carcinomaChin. Med. Sci. J.16223226Google Scholar
  30. 30.
    Vanhoefer, U., Cao, S., Harstrick, A., Seeber, S., Rustum, Y. M. 1997Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)Ann. Oncol.812211228Google Scholar
  31. 31.
    Fossella, F. V. 1999Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trialsSemin. Oncol.261723Google Scholar
  32. 32.
    Hoffman, R. M. 1991Three-dimensional histoculture: origins and applications in cancer researchCancer Cells38692Google Scholar
  33. 33.
    Fossella, F., Pereira, J. R., Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczesna, A., Fidias, P., Millward, M., Belani, C. P. 2003Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study groupJ. Clin. Oncol.2130163024Google Scholar
  34. 34.
    Rigas, J. R. 2004Taxane-platinum combinations in advanced non-small cell lung cancer: a reviewOncologist9:1623Google Scholar
  35. 35.
    Roa, V., Conner, A., Mitchell, R. B. 1998Carboplatin and paclitaxel for previously treated patients with non-small-cell lung cancerCancer Investig.16381384Google Scholar
  36. 36.
    Belani, C. P. 1998Single agents in the second-line treatment of non-small cell lung cancerSemin. Oncol.251014Google Scholar
  37. 37.
    Sato, S., Kigawa, J., Kanamori, Y., Itamochi, H., Oishi, T., Shimada, M., Iba, T., Naniwa, J., Uegaki, K., Terakawa, N. 2004Activity of docetaxel in paclitaxel-resistant ovarian cancer cellsCancer Chemother. Pharmacol.53247252Google Scholar
  38. 38.
    Witters, L. M., Santala, S. M., Engle, L., Chinchilli, V., Lipton, A. 2003Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cellsAm. J. Clin. Oncol.265054Google Scholar
  39. 39.
    Stein, C. A., LaRocca, R. V., Thomas, R., McAtee, N., Myers, C. E. 1989Suramin: an anticancer drug with a unique mechanism of actionJ. Clin. Oncol.7499508Google Scholar
  40. 40.
    Falcone, A., Antonuzzo, A., Danesi, R., Allegrini, G., Monica, L., Pfanner, E., Masi, G., Ricci, S., Tacca, M., Conte, P. F. 1999Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinomaCancer86470476Google Scholar
  41. 41.
    Rosen, P. J., Mendoza, E. F., Landaw, E. M., Mondino, B., Graves, M. D., McBride, J. H., Turcillo, P., deKernion, J., Belldegrun, A. 1996Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacyJ. Clin. Oncol.1416261636Google Scholar
  42. 42.
    Mirza, M. R., Jakobsen, E., Pfeiffer, P., Lindebjerg-Clasen, B., Bergh, J., Rose, C. 1997Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studiesActa Oncol.36171174Google Scholar
  43. 43.
    Falcone, A., Pfanner, E., Brunetti, I., Allegrini, G., Lencioni, M., Galli, C., Masi, G., Danesi, R., Antonuzzo, A., Tacca, M., Conte, P. F. 1998Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapyTumori84666668Google Scholar
  44. 44.
    Hussain, M., Fisher, E. I., Petrylak, D. P., O’Connor, J., Wood, D. P., Small, E. J., Eisenberger, M. A., Crawford, E. D. 2000Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group studyJ. Clin. Oncol.1810431049Google Scholar
  45. 45.
    Miglietta, L., Canobbio, L., Granetto, C., Vannozzi, M., Esposito, M., Boccardo, F. 1997. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of apilot phase II studyJ. Cancer Res. Clin. Oncol.123407410Google Scholar
  46. 46.
    Motzer, R. J., Dmitrovsky, E., Miller, W. H., Tong, W. P., Bajorin, D. F., Scher, H. I., Bosl, G. J. 1993Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trialCancer7233133317Google Scholar
  47. 47.
    Rapoport, B. L., Falkson, G., Raats, J. I., Wet, M., Lotz, B. P., Potgieter, H. C. 1993Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical studyAnn. Oncol.4567573Google Scholar
  48. 48.
    Dreicer, R., Smith, D. C., Williams, R. D., See, W. A. 1999Phase II trial of suramin in patients with metastatic renal cell carcinomaInvest. New Drugs17183189Google Scholar
  49. 49.
    Howard, S. P., Park, S. J., Hughes-Davies, L., Coleman, C. N., Price, B. D. 1996Suramin increases p53 protein levels but does not activate the p53-dependent G1 checkpointClin. Cancer Res.2269276Google Scholar
  50. 50.
    Palayoor, S. T., Bump, E. A., Teicher, B. A., Coleman, C. N. 1997Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suraminRadiat. Res.148105114Google Scholar
  51. 51.
    Qiao, L., Pizzolo, J. G., Melamed, M. R. 1994Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 carcinoma cellsBiochem. Biophys. Res. Commun.201581588Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Ze Lu
    • 1
    • 2
  • Trini S.-S. Wientjes
    • 2
  • Jessie L.-S. Au
    • 1
  1. 1.College of PharmacyThe Ohio State UniversityColumbusUSA
  2. 2.Optimum Therapeutics, LLCColumbusUSA

Personalised recommendations